Skip to main content
Premium Trial:

Request an Annual Quote

Silence Inks Tech-Evaluation Deal with Miragen

Premium

Silence Therapeutics announced this week that it has signed a deal under which Miragen will evaluate its microRNA therapeutic candidates in combination with Silence's cationic lipid-based DBTC delivery technology.

Miragen will provide Silence with multiple specific miRNA sequences, which Silence will formulate with the DBTC technology. Miragen will then examine the compounds in vitro and in vivo, and have the option to select lead candidates for further development as therapeutics.

Additional terms of the arrangement were not disclosed.

“This is the third collaboration that we have recently signed to explore the use of Silence's delivery technologies for microRNAs,” Silence CEO Thomas Christely said in a statement. “Whilst we remain internally focused on the delivery of our siRNA therapies, we continue to broaden the potential value of our proprietary delivery systems by collaborating with partners.”

In October, Silence inked a DBTC-evaluation deal with Mirna Therapeutics (GSN 10/27/2011), although Mirna recently announced that it was going to use Marina Biotech's Smarticle lipids with numerous drug candidates (GSN 1/5/2012).

A month before that, Silence announced that InteRNA Technologies would examine Silence's core AtuPlex lipid delivery technology in combination with its own miRNA mimics (GSN 9/15/2011).

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.